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CASE PRESENTATION
A 54-year-old woman was injured in a motor vehicle
accident and underwent partial nephrectomy that sub-
sequently revealed diabetic nephropathy. The histologic
tissue available was generous compared to that available
for standard clinical biopsies. The patient developed dia-
betes mellitus at age 42; at the time of the resection, she
had had diabetes for 11 years. She was initially treated
with diet and oral hypoglycemic agents, but by the age of
50 required insulin to maintain glycemic control. She has
hypercholesterolemia. She is hypertensive and had a my-
ocardial infarction at age 52. She was never a cigarette
smoker. She has not had laser therapy and is seen reg-
ularly by an ophthalmologist. Apart from insulin, her
medications included metoprolol, furosemide, amlodip-
ine, amiodarone, atorvastatin, isosorbide dinitrate, as-
pirin, and erythropoietin.
Her family history is highly significant (Fig. 1). Details
regarding her maternal grandmother are sketchy, but she
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is believed not to have had diabetes mellitus. The patient’s
maternal grandfather was diabetic, but little is known
of his diabetic complications. Her paternal grandmother
and grandfather both had diabetes and myocardial in-
farctions. Her mother was diabetic and had retinopa-
thy, nephropathy, and cardiovascular disease. Her father
was diabetic without known complications. Both par-
ents developed diabetes during their thirties and were
treated with oral hypoglycemic agents. The patient has
four brothers, all of whom developed diabetes in their for-
ties. The three who have had diabetes for 2, 5, or 14 years
have had no complications. The fourth sibling, who has
had diabetes for 9 years, has nephropathy and retinopa-
thy and had a myocardial infarction.
A peritoneal dialysis catheter was placed in the patient,
and dialysis is anticipated to begin in the next few weeks.
The patient’s physical examination was remarkable
only for hypertension (blood pressure, 150/95 mm Hg),
obesity (weight, 235 pounds; height, 5′ 4′′), background
diabetic retinopathy, and 2+ bilateral leg edema. Labora-
tory examination revealed a serum creatinine of 5 mg/dL,
a random urinary protein/creatinine ratio of 11.4, and a
hemoglobin A1c (HbA1c) of 6.1%.
The renal resection provided more than 100 glomeruli
for light microscopy (Fig. 2). Roughly 25% of these were
completely sclerotic. A few of the remainder showed is-
chemic capillary wall wrinkling. Arterial walls were thick-
ened with intimal fibrosis. Arteriolar walls had prominent
thickening with hyalinization (insudates). The nonob-
solescent glomeruli all were abnormal and similar to
each other, demonstrating increased mesangial matrix ar-
ranged as one or more acellular or hypocellular nodules in
each glomerulus. Some glomeruli had segmental mesan-
giolysis and others had insudative lesions occluding some
capillary lumina. Marked tubular atrophy with interstitial
fibrosis was present. The fibrotic interstitium contained
few lymphocytes. More than 30 glomeruli were avail-
able for immunofluorescence microscopy. The tissue was
stained with fluoresceinated anti-sera to IgG, IgM, IgA,
C3, C1q, fibrin, and lambda and kappa light chains. IgG
and albumin were present in all basement membranes in a
“pseudolinear” pattern. In approximately 20%, IgM and
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Fig. 1. Pedigree of the index case (arrow).
C3 were present in a coarsely granular and amorphous
pattern in a segmental distribution. Of the 23 glomeruli
available for electron microscopy, four were completely
sclerotic. No arteries were present. Arteriolar walls were
thickened with insudative lesions. Most capillary lumina
were patent, although a few in two or three glomeruli
were occluded by insudative lesions. Capillary walls were
single contoured. Mild to moderate tubular atrophy and
interstitial fibrosis were present. Ultrastructural exam-
ination showed expanded mesangial matrix consistent
with the findings on light microscopy as well as thickened
glomerular basement membranes (GBMs). The foot pro-
cesses of visceral epithelial cells were nearly completely
effaced. Neither electron-dense deposits nor abnormal
inclusions were present.
The proband and her siblings agreed to participate
in the Families Investigating Nephropathy and Diabetes
(FIND) study, a National Institutes of Health-sponsored
consortium with the goal of identifying genes and/or chro-
mosomal segments with linkage to diabetic nephropathy
[1]. An enduring gene bank comprising DNA from trans-
formed lymphocytes will be available at the conclusion
of the FIND study that will identify genetic contributions
to diabetes and its complications.
DISCUSSION
DR. SHARON ADLER (Associate Chief, Division of
Nephrology and Hypertension, Harbor-UCLA Medical
Center, and Professor of Medicine, UCLA School of
Medicine, Torrance, California, USA): This patient’s fam-
ily history turns out to be very instructive (Fig. 1) and I
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Fig. 2. Renal histopathology of the lesions present. (A) Arterial walls
were thickened with intimal fibrosis. (B) Arteriolar walls had prominent
thickening with hyalinization (insudates) in afferent and efferent arte-
rioles characteristic of patients with diabetes. (C) Some glomeruli had
segmental mesangiolysis. (D) Others had insudative lesions occluding
some capillary lumina. (E) Nonobsolescent glomeruli were all abnor-
mal and similar, demonstrating increased mesangial matrix arranged
as acellular or hypocellular nodules in each glomerulus. (F) There was
marked tubular atrophy with interstitial fibrosis and few lymphocytes
in the fibrotic interstitium.
will use this family tree to weave together the histology,
cell biology, and genetics of diabetic nephropathy.
It is widely recognized that mesangial expansion is
the defining lesion in diabetic nephropathy. But the pro-
cess is more extensive, and the biopsy specimen of the
proband in this Forum reflects the lesion in its greater
complexity, involving all four geographic renal regions:
arteries/arterioles, mesangium, glomerular capillary wall,
and tubulointerstitium.
The mesangial expansion encroaches on capillary lu-
mena and results in slow progression toward end-stage
renal disease. But the diabetic lesion also involves
podocyte injury mediated by signal transduction change,
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cytoskeletal change, alterations in the podocyte slit pore
membrane, detachment from the GBM, and apoptosis,
all of which contribute to the development of protein-
uria. In turn, proteinuria accelerates progression by its
effects on tubulointerstitial fibrosis and atrophy, the fi-
nal common pathway of progressive renal insufficiency.
Adding insult to injury are the arterial and arteriolar scle-
rotic lesions, which superimpose ischemia on each of the
other three renal regions. For the purposes of this discus-
sion, I will use the effects of angiotensin II as a model
for examining the pathogenesis of diabetic nephropathy
in the vasculature, mesangium, glomerular capillary wall,
and tubulointerstitium.
Why focus on angiotensin II rather than glucose? In
essence, by examining only the renal-angiotensin system
(RAS), I intend to oversimplify the diabetic complication
paradigm to a single critical downstream effect of the
hyperglycemic milieu. In so doing, I will use the RAS
sometimes to show synergistic effects of glucose and
sometimes as a surrogate for glucose effect. I’d like to
focus on the mechanisms through which angiotensin II
interacts on the cell membrane with its receptor(s), and
then triggers the elaboration of signaling molecules, the
activation of transcription factors, and the up-regulation
of gene expression, ultimately inducing the fibrosis, cell
growth, and even the inflammation that characterize the
renal damage in diabetic nephropathy. Ultimately I’d like
to leave you with the concept that the RAS is an excel-
lent model that allows us to study the redundancy and the
convergence of multiple systems in the cellular pathogen-
esis of diabetic nephropathy. For instance, angiotensin II
interacts with many other growth factors and cytokines
that also are activated in diabetic nephropathy and that si-
multaneously utilize the same and parallel signaling path-
ways, all factors or systems contributing to the histologic
picture and functional decline of the diabetic kidney.
Vasculature
Our proband had classic lesions of hyalinosis in affer-
ent and efferent arterioles. What role might these changes
be playing and what induces these changes? Arteriolar
hyalinosis, extremely common in diabetic nephropathy,
occurs four to five times as frequently in diabetics as it
does in controls [2], and it progresses with time [3]. In the
study by Fioretto et al [3], in which patients with type 2
diabetes had a baseline and a follow-up biopsy on aver-
age 5.6 years apart, arteriolar hyalinosis almost doubled.
In fact, a comprehensive scoring system for pathologic
changes in diabetic nephropathy that included a vascular
component predicted the outcome of patients with dia-
betic nephropathy well [abstract; Bertani T et al, J Am
Soc Nephrol 14:397A, 2003]. The vascular part was given
just as much weight as the glomerular and the tubulointer-
stitial components in this comprehensive scoring system.
The data demonstrated that if the composite score was
greater than 10, subjects were twice as likely to die dur-
ing the 6- to 8-year period of follow-up, whereas if the
score was less than 10, the patient’s chances of surviving
without dialysis were substantially greater.
Angiotensin II certainly contributes to the develop-
ment of these arterial and arteriolar lesions. Let’s look at
the downstream signaling pathways it utilizes to induce
these changes. Acting in an endocrine fashion, an-
giotensin II engages the angiotensin type 1 (AT1) recep-
tor in the cell membrane of the vascular smooth mus-
cle cell (VSMC) and activates mitogen-activated protein
kinase (MAPK) signaling comprised of JNK, ERK, and
p38, the latter additively with hyperglycemia. Using
cultured VSMCs, Natarajan et al [4] demonstrated that
high-glucose media increased expression of the MAPK
signaling molecules ERK, JNK, and p38 about 2.5- to
3.5-fold. Angiotensin II increased ERK, JNK, and p38
similarly [4], but the effects of high-glucose media and
angiotensin II were synergistic in the case of ERK, in-
creasing eightfold, and p38, increasing fourfold.
These signaling molecules then stimulate nuclear tran-
scription factors, which are activated molecules that
bind to genes in the nucleus and enhance transcrip-
tion. The activating protein-1 (AP-1) and cyclic adeno-
sine monophosphate (AMP) response element-binding
(CREB) proteins are two of the nuclear transcription
factors activated by angiotensin II. Transcription fac-
tor activity is measured by a technique called elec-
trophoretic mobility shift assay, which demonstrates
binding of the transcription factor to DNA. The addi-
tion of angiotensin II activates AP-1 DNA-binding ac-
tivity in a dose-dependent manner in VSMCs cultured
in media of normal glucose concentration and additively
in high-glucose media [4]. CREB activity in VSMCs is
also increased by angiotensin II via pathways involv-
ing p38 MAPK and ERK, mechanisms delineated by
the use of specific inhibitors for these pathways [4, 5].
CREB is of great interest because it binds to a specific se-
quence in the fibronectin gene and can therefore enhance
the transcription of fibronectin. Because fibronectin is
a matrix molecule, this activation would specifically in-
crease mesangial expansion, thus facilitating fibrosis. In
addition, a novel 12/15-lipoxygenase (12/15-LO) lipid-
mediator signaling pathway has been elucidated that
mediates the actions of angiotensin II [4]. In fact, the
product of 12/15-LO, 12-hydroxyeicosatetraenoic acid
(12-HETE), simulates many of the cellular functions of
angiotensin II itself [4]. Furthermore, in VSMCs, if the
12/15-LO enzyme is inhibited in vitro, angiotensin II–
induced CREB activation is abrogated [4]. Similarly, the
inhibition of p38 MAPK, ERK, and 12-HETE signaling
molecules inhibits the transcription of fibronectin [4].
Let me summarize. In VSMCs, angiotensin II binds to
its AT1 receptor, and in the presence of a high-glucose
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environment activates the signaling molecules ERK,
JNK, and p38 MAPK, as well as the novel 12-HETE
lipid mediator-signaling pathway, to stimulate the ac-
tivity of transcription factors CREB and AP-1. These
molecules then induce gene transcription and stimulate
matrix synthesis (fibronectin) and cell growth, cardinal
features of diabetic nephropathy. In VSMCs in vitro, an-
giotensin II stimulates both hyperplasia and hypertrophy,
the latter additively in the presence of a high-glucose
environment [4–6]. This leads to arteriolar nephroscle-
rosis, which today’s patient and most patients with di-
abetic nephropathy have. That same process also could
contribute to ischemic nephropathy superimposed on the
classical renal parenchymal lesions with which we are
most familiar. The fact that these pathways can be inhib-
ited in vitro is critical because in vitro inhibition suggests
the potential for therapeutic manipulation. Most inter-
esting is the suggestion that inhibition of these pathways
offers synergism with angiotensin II synthesis or receptor
blockade.
Glomerulus
I will now turn to the glomerulus. Brenner’s seminal
work in 1983 showed that angiotensin II largely medi-
ates glomerular hypertension in diabetic nephropathy [7].
This fundamental observation drove our current use of
angiotensin-converting enzyme (ACE) inhibitors and an-
giotensin receptor blockers in the treatment of diabetic
nephropathy but also other proteinuric renal diseases.
The work by Lewis et al [8], now more than 10 years old,
showed a 50% risk reduction in a composite end point
of doubling of the serum creatinine, the risk of reaching
end-stage renal disease, and the risk of dying in patients
with diabetic nephropathy due to type 1 diabetes. More
recently, careful clinical studies have shown that in pa-
tients with type 2 diabetes and nephropathy, angiotensin
receptor blockers reduced the relative risk of reaching
the composite end point by 20% to 28% [9, 10]. These
landmark studies have provided us with tools that have
revolutionized our ability to help patients with diabetic
nephropathy; nevertheless we still can only reduce com-
posite risks by 20% to 50%, so clearly we need additional
therapeutic strategies.
Mesangium
Let us turn, then, to the mesangium. As I men-
tioned, mesangial expansion is the defining histologic
feature of diabetic nephropathy. The classic paper by
Mauer et al [11] in 1984 demonstrated a relationship be-
tween declining creatinine clearance and an expanding
mesangium. Mesangial cells express the entire RAS, in-
cluding angiotensinogen, renin, angiotensin I, ACE, and
angiotensin II. In fact, in mesangial cells incubated in
vitro with medium of high glucose content, both mRNA
and immunoreactivity for angiotensinogen increase. This
alteration raises the levels of angiotensin I, angiotensin
II, and very interestingly, a novel peptidase that seems
to convert angiotensin 1-9 to angiotensin II [12]. In the
mesangial cell, then, high-glucose levels stimulate syn-
thesis of angiotensin II. This stimulation raises the possi-
bility that elucidation of signaling in this cell type might
uncover additional pathways for inhibition in the clinical
setting.
Mesangial cell angiotensin II signaling recapitulates
the signaling observed in VSMCs. This signaling begins
with an angiotensin II-AT1 receptor interaction and ac-
tivation of the MAPKs. In addition, concomitant elabo-
ration of phospholipases releases arachidonic acid from
the cell membrane and facilitates its metabolism to the
novel lipid signaling molecule, 12-HETE, by the action
of leukocyte-type 12/15-LO. Angiotensin II increases
12/15-LO mRNA expression and 12-HETE release in
rat mesangial cells [13]. Just as in VSMCs, angiotensin
II (and, parenthetically, serum) induces rapid phospho-
rylation of p38 MAPK via a pathway that is dependent
upon 12/15-LO expression [13]. Of interest is the fact that
mesangial cells from knockout mice that lack the leuko-
cyte 12/15 LO enzyme fail to phosphorylate p38 MAPK
on stimulation with angiotensin II; this finding demon-
strates that downstream signaling by angiotensin II oc-
curs, at least in part, through this 12/15-LO pathway [13].
Subsequently, angiotensin II in mesangial cells acti-
vates transcription factors such as CREB just as it does in
VSMCs [13]. When mesangial cells from wild-type mice
are incubated with angiotensin II, CREB is phosphory-
lated. By contrast, mesangial cells from 12/15-LO knock-
out mice fail to phosphorylate CREB after incubation
with angiotensin II. As a result, one would predict that in
mesangial cells derived from wild-type mice, angiotensin
II would induce proliferation and hypertrophy, but not
in mesangial cells derived from 12/15-LO knockout mice.
In fact, that is precisely what is observed. These in vitro
experiments further demonstrated that 12-HETE– and
angiotensin II–induced hypertrophy also depend on p38
MAPK phosphorylation [13].
Similar phenomena are observed with respect to matrix
synthesis. As in VSMCs, angiotensin II increases mesan-
gial cell fibronectin synthesis. Interestingly enough, the
increment is about the same magnitude as that ob-
served with incubation with 12-HETE, the lipid-signaling
molecule, and that’s true both for cell-associated and
released fibronectin [13]. Experiments utilizing wild-
type mesangial cells and mesangial cells transfected with
ribozyme or (scrambled) ribozyme for the 12/15-LO en-
zyme demonstrated that the 12/15-LO pathway is criti-
cal for fibronectin elaboration as a result of angiotensin
II stimulation. Wild-type mesangial cells stimulated with
angiotensin II increased fibronectin expression by about
1.5-fold. However, mesangial cells transfected with the
ribozyme that inhibits 12/15-LO expression failed to
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respond to angiotensin II with fibronectin synthesis. Con-
trol (scrambled) ribozyme had no effect [13]. These stud-
ies demonstrate that angiotensin II acts on mesangial cells
and VSMCs use angiotensin II through similar signaling
pathways. In each cell type, angiotensin II binds to the
AT1 receptor; interacts with an enriched glycemic envi-
ronment; releases arachidonic acid through phospholi-
pases; liberates the novel signaling molecule 12-HETE;
activates JNK, ERK, and p38 MAPK; activates transcrip-
tion factors; and induces cell growth and extracellular
matrix (ECM) synthesis.
In vivo relevance
What is the evidence that these pathways are rele-
vant in vivo? In rats with streptozotocin-induced dia-
betes, glomerular 12/15-LO mRNA and protein were up-
regulated 1, 2, 3, and 4 months after diabetes induction as
demonstrated by reverse transcription-polymerase chain
reaction (RT-PCR) and by Western analysis and im-
munohistochemistry, respectively [14]. Upstream of p38
MAPK is the signaling molecule MKK3/6, which is ac-
tivated during the first 2 months in diabetic rats com-
pared to controls [14]. A similar pattern was observed for
phospho-p38 MAPK and phospho-CREB. At 4 months,
mesangial (and, parenthetically, podocyte) fibronectin
accretion was increased; this phenomenon presumably
contributes to mesangial expansion [14]. I will loosely
refer to this change as glomerulosclerosis. Thus, in dia-
betic rats, just as in mesangial cells and VSMCs in vitro,
angiotensin II and high ambient glucose concentration
activate a novel lipid-mediating signal transduction path-
way, and in conjunction with MAPKs and transcription
factors, lead to fibronectin synthesis; this process then ac-
celerates renal disease.
It turns out that angiotensin II interactions are more
complex than the simple model we have described so
far. For instance, angiotensin II stimulates transform-
ing growth factor-b (TGF-b) expression [15]. In cultured
mesangial cells, incubation with angiotensin II induces
time- and dose-dependent increases in TGF-b mRNA
and activity and stimulates synthesis of ECM molecules
[16]. Furthermore, if mesangial cells are stimulated with
angiotensin II in the presence of TGF-b antibody, an-
giotensin II does not stimulate matrix synthesis [16]; this
finding implicates TGF-b in angiotensin II–stimulated
matrix synthesis. In a variety of experimental models of
nephropathy, including remnant kidneys, SHR hyperten-
sion, immune-complex glomerulonephritis, ureteral ob-
struction, and radiation nephritis, ACE inhibitors and
angiotensin receptor blockers decrease TGF-b expres-
sion [15]. However, the resulting TGF-b inhibition is usu-
ally incomplete, leaving open the possibility that “direct”
TGF-b inhibition might be synergistic with angiotensin II
inhibition. Remuzzi’s group tested this hypothesis in re-
cently published work demonstrating that superimposing
TGF-b inhibition on ACE inhibition further diminished
proteinuria in rats with established diabetic nephropa-
thy [17]. Thus, dissecting these pathways and examining
their interactions provides an opportunity for the devel-
opment of novel therapies that will further diminish the
risk of progressive renal disease.
Podocyte
I now would like to turn to the podocyte. Podocytes
are different than VSMCs and mesangial cells. Never-
theless, clear-cut evidence shows podocyte injury in dia-
betes. Podocyte effacement occurs and is ameliorated by
ACE inhibitors [18, 19]. Podocyte number is diminished
and correlates with albuminuria [20, 21] [abstract; Dalla
Vestra M et al, J Am Soc Nephrol 11:113A, 2000] and
podocytes are excreted in the urine in diabetic nephropa-
thy [22, 23] as well as in other renal diseases. Podocytes
have come of age from the perspective of experimental
investigation in the last 5 years. While most of us were
taught that albuminuria and proteinuria arise from ab-
normalities in the GBM, it is now apparent that podocyte
dysfunction is an important cause of proteinuria. This
knowledge initially arose from the identification of
nephrin as the major protein component of the slit pore
membrane [24], but many more podocyte structural pro-
teins have now been implicated in the development of
proteinuria (reviewed in [25]).
Currently, our knowledge regarding components of
the RAS that are expressed in and on podocytes is in-
complete. We know that podocytes bear AT1 receptors.
Recently, other RAS components have been identified,
including the AT2 receptor, ACE 2, and chymase [26]
[abstract; Hamming I, J Am Soc Nephrol 14:412A, 2003].
The question is, does the RAS play a role in diabetic
albuminuria? In cultured podocytes incubated with an-
giotensin II, nephrin expression decreases acutely [27].
The podocytes can escape that inhibition, but the data
nevertheless suggest a direct relationship between an-
giotensin II and the maintenance of nephrin. Ultrastruc-
tural and immunohistochemical studies have shown that
nephrin is also diminished in the glomeruli of diabetic rats
[19, 28]. In rats with experimental diabetes for 6 months,
the number of slit pore membranes per length of GBM
is diminished, and this change signifies podocyte efface-
ment. Recall that today’s patient had nearly complete
podocyte effacement. Perhaps this mechanism is involved
in the development of podocyte effacement in diabetic
patients. Interestingly enough, if the diabetic rats were
treated either with an ACE inhibitor or an angiotensin
receptor blocker, the number of slit pore membranes
per length of GBM was preserved [19]. This appears to
be the case in humans as well. A study by Langham et
al [29] revealed that nephrin mRNA is diminished in
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diabetics and that ACE inhibition preserves nephrin
mRNA expression. This is not just true for nephrin
mRNA; it is also true for the protein. Glomerular nephrin
demonstrated by immunofluorescence microscopy is di-
minished in microalbuminuric patients with type 1 dia-
betes and in overtly proteinuric patients with either type
1 or type 2 diabetes [27]. These data suggest that an-
giotensin II actually might modulate the proteinuria in
diabetic nephropathy, at least in part, by ameliorating
diabetes-induced changes in nephrin synthesis.
Another important aspect of diabetic nephropathy
pathologically is hypertrophy. Podocytes are terminally
differentiated cells and do not divide under physio-
logic conditions, although they do in pathologic con-
ditions. In diabetes, as in other glomerular diseases,
podocytes are lost in urine. As a result, there is a stim-
ulus for podocyte hypertrophy as the diminished num-
ber of podocytes covers the GBM [30]. In diabetic rats
treated with ACE inhibitors, hypertrophy is diminished
and podocyte number is preserved [30]. The latter does
not look like a nephrin effect, yet it acts through an an-
giotensin receptor–mediated process. Clearly, the role
of the RAS on podocyte biology is complex. The RAS
might induce albuminuria in diabetic nephropathy in part
by its effects on nephrin and on the podocyte slit pore
membrane. Other effects, some angiotensin II–mediated,
and probably many others that are not, remain to be
determined.
Tubulointerstitium
The tubulointerstitium behaves more like mesangium
and VSMCs than like podocytes, at least as it relates to
angiotensin II. Like the mesangium, tubular and intersti-
tial cells express components of the RAS. In rat proximal
tubular cells, high glucose levels increase angiotensino-
gen gene expression via the p38 MAPK pathway [31].
In fact, the RAS proteins are altered in the tubulointer-
stitium in diabetic nephropathy. Angiotensin-converting
enzyme is increased in tubules and there is neoinduction
in interstitial cells, particularly in alpha-actin–positive
cells. Angiotensin II is increased both in tubular and in-
terstitial cells. However, the ratio of the AT1-to-AT2 re-
ceptor is lower in tubular cells in diabetic kidneys than
in normal ones [32]. Just as in VSMCs and mesangial
cells, these changes in the RAS are associated with in-
creased tubular signaling, TGF-b elaboration, hypertro-
phy, and ECM synthesis. In tubular cells, angiotensin II
activates nuclear factor-jB (NF-jB) via the AT1 recep-
tor [33]; this activation then induces hypertrophy and in-
creases type IV collagen production. Again, as in VSMCs,
a high glucose environment up-regulates this process in a
synergistic fashion [34–36]. It is worthwhile to also point
out that in tubules, angiotensin II mediates some of its
actions through novel translational effects as described
for VEGF [abstract; Feliers D et al, J Am Soc Nephrol
14:402A, 2003] and not always by transcriptional effects.
The same process is observed in fibroblasts. In cultured
fibroblasts, angiotensin II induces proliferation and in-
creased ECM synthesis via a TGF-b–dependent pathway
[37]. Furthermore, both proliferation and fibronectin syn-
thesis are mediated via the AT1, but not the AT2, receptor
[37]. Thus, in a manner analogous to the process in mesan-
gial cells, there are interactions between angiotensin II
and TGF-b in fibroblasts in vitro.
The cell culture data are relevant for the in vivo sit-
uation. Angiotensin II infused into rats induces tubu-
lar atrophy, monocyte infiltration, and interstitial fibrosis
[38]; these findings are reminiscent of those in our in-
dex case. Furthermore, as is the case for the mesangium
and the vasculature, ACE inhibitors limit tubulointer-
stitial damage [29]. Thus, VSMCs, mesangial cells, and
the cells of the tubulointerstitium are similar with regard
to the effects of the RAS. In each, the AT1 receptor is
activated. Downstream signaling activates nuclear tran-
scription factors, inducing the transcription of certain
damaging genes, which cause the hypertrophy, possibly
hyperplasia, fibrosis, and sclerosis that characterize dia-
betic nephropathy.
Genetic predisposition
Finally, how does genetic predisposition affect the ac-
tivity of these pathways to confer protection or risk? The
literature abounds with evidence for genetic mediation of
the initiation and progression of diabetic nephropathy.
First, there is familial clustering that is not completely
explained by environmental factors [39–47]. Our index
case and her family are perfect examples of genetic pre-
disposition to diabetes and its complications, or, at the
very least, familial clustering. Parving and colleagues es-
timated that glycemic control, hypertension, and albu-
minuria account for only one-third of the variability of
progression rates in diabetic nephropathy [48]. Second,
the incidence of diabetic complications varies according
to ethnicity [49–53]. Finally, evidence from animal mod-
els demonstrates strain-specific predisposition to certain
complications, in a setting in which environmental factors
can be virtually eliminated as causative. For instance, ob-
servations in mice raised the possibility of “renal failure
genes.” Rf1 and Rf2 are genes that predispose to renal
failure in the fawn-hooded rat, which develops hyperten-
sion, nephrosclerosis, and glomerulosclerosis [54]. Taken
together, these data suggest a genetic cause for the initi-
ation and progression of diabetic complications.
Two methods are commonly used to assess the genetic
contributions to disease processes: candidate gene anal-
ysis, which is hypothesis driven; and genomic scanning,
which discerns the contributions of unsuspected genes or
chromosomal regions. Candidate genes of the RAS have
been extensively studied. Numerous publications have
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been reported in the English and non-English medical
literature on the effects in diabetic nephropathy of poly-
morphisms in the angiotensinogen gene [55–61]; the AT1
receptor [62–65]; and the ACE gene [65]. Overall, the
results are relatively inconclusive. A meta-analysis that
attempted to enhance the power of the individual obser-
vations found increased risk for diabetic nephropathy in
patients bearing the deletion polymorphism of the ACE
gene, either in the homozygous or heterozygous state, and
the relative risk conferred was estimated to be a factor of
about 1.3 [65]. Although this conclusion is encouraging
and suggests that this polymorphism might be a diabetic
nephropathy risk gene, the magnitude of the effect is rel-
atively small. In fact, it is possible that genetic predispo-
sition of diabetic nephropathy does not originate from a
small number of genes with large effects, but rather from
a large number of genes with small effects. Family-based
genetic strategies have greater power to detect the for-
mer; association strategies have greater power to detect
the latter [66].
Given the complexity and redundancy of the pathways
we have been examining, and the possibility that genetic
predisposition can best be modeled by the sum of a mod-
erate number of small effectors, experiments that rely less
on hypothesis-based approaches and more on examin-
ing the multiplicity of pathways as hypothesis generators
would be beneficial. Using Affymetrix U133A chips, Liu
et al performed gene expression profiling on glomerular
mRNA obtained from renal biopsy specimens of patients
with diabetic nephropathy. Significant changes in gene ex-
pression, either up-regulation or down-regulation, were
noted in 182 genes [abstract; Liu Z-H, J Am Soc Nephrol
14:400A, 2003]. This work suggests opportunities for sub-
sequent hypothesis generation and testing.
Genomic scanning also is hypothesis-independent ex-
perimentation and facilitates the discovery of genes or
chromosomal regions that might be unsuspected but are
implicated by linkage analysis to diabetic nephropathy.
In Pima Indians, regions on chromosomes 3, 7, 9, and 20
with linkage to diabetic nephropathy have been reported
[67]. In whites with type-1 diabetes and nephropathy, a
region on chromosome 3q links to diabetic nephropathy
but is not proximate to the AT1 receptor, which also re-
sides on 3q [68]. In whites, linkage of chromosomes 12 and
20 to diabetic nephropathy has been demonstrated [69].
Most recently, a region on chromosome 10 was implicated
in whites with diabetic nephropathy and end-stage renal
disease [70]. This region appears to be distant from a less
significant minor peak in the region on the same chro-
mosome in which the human homologue of mouse Rf1
resides. In African Americans, weak linkage was noted
with 10p, but none with 10q in the region of the Rf1 ho-
mologue [71]. Taken together, the inconsistencies in can-
didate gene and family studies suggest the possibility that
a moderate number of small gene effects might very well
be the best model for assessing genetic predisposition to
diabetic nephropathy. Furthermore, new tools have taken
us beyond the microsatellite markers used to assess ge-
netic predisposition in the family studies so far published.
Completion of the human genome map has given us an-
other method for scanning the genome–single nucleotide
polymorphism (SNP) mapping [72]. SNP haplotyping is
expected to improve the efficiency of testing for diabetic
nephropathy chromosomal regions. SNPs are individual
variations in gene sequence that tend to regulate pro-
tein expression more than protein structure. They are or-
ganized into DNA blocks called haplotypes, and these
haplotype blocks are inherited without recombination
over many generations [72]. Mapping the haplotypes in-
creases the efficiency of identifying genetic variations as-
sociated with disease, and this new approach might prove
more powerful than the standard microsatellite mapping.
Whereas classic linkage analysis is done in families, SNP
studies are usually done initially in case-control popula-
tions. The FIND study has two large case-control popula-
tions of Mexican Americans and African Americans that
can be utilized to perform SNP haplotyping to scan the
genome to look for SNPs.
Let me summarize. Numerous candidate genes and
chromosomal regions have been reported as risk factors
for the initiation or progression of diabetic nephropathy.
The ACE insertion/deletion polymorphism is possibly a
diabetic risk gene, but it isn’t the diabetic risk gene with a
major effect that has been sought, as it is estimated only
to increase risk by a maximum of approximately 1.3-fold
[65]. The FIND study soon will have the result from the
first half of the patients entered into its family-based link-
age analysis, yielding data on the largest population of
subjects with diabetic nephropathy so far assembled [1].
Future challenges, apart from finding genes with more
powerful risk contributions, will involve understanding
how these genes confer risk; assessing similarities and dif-
ferences in risk genes in different ethnic populations; as-
sessing gene-gene interactions and gene-environmental
interactions as a potential explanation for the varied re-
sults observed so far; and understanding the biologic im-
pact of SNP polymorphisms for diabetic nephropathy
risk, as their impact on protein function might exceed
their impact on protein structure.
I should underscore the fact that this discussion has
been a simplified review of the relationships among
glycemia, the RAS, histopathologic change, and the ge-
netics of diabetic nephropathy, but its simplification al-
lows us to underscore certain principles. In the redundant
path of this biology, angiotensin II stimulates and inter-
acts with a large number of other molecules. These are
just a few of the major ones: glut-1, tumor necrosis factor-
a (TNF-a), platelet-derived growth factor (PDGF),
connective tissue growth factor (CTGF), basic fibrob-
last growth factor (bFGF), insulin-like growth factor-1
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(IGF-1), advanced glycosylation end products (AGEs)
(pentosidine), reactive oxygen species (ROS), oxidized
low-density lipoprotein (LDL), vascular cell adhesion
molecule (VCAM-1), osteopontin, NF-jB, RANTES
(particularly in glomerular endothelial cells), and mono-
cyte chemotactic protein (MCP). In closing, I’d like to
leave you with the top 10 principles detailed by this
discussion: (1) signaling systems, with their complexity
and redundancy, are systems of great beauty, reflective
of evolutionary order; (2) differentiated biologic tissues
often use the same tools to achieve tissue-specific func-
tions and express tissue-specific pathology; (3) diabetic
nephropathy reflects cellular injury due to common bio-
logic pathways manifested in different cell types/regions
of the kidney; (4) the kidney’s susceptibility to glomeru-
losclerosis and tubulointerstital fibrosis reflects the im-
pact of the renal RAS and its interactions with other
profibrotic molecular pathways; (5) defining these inter-
actions and the downstream signaling mechanisms me-
diating them lays the foundation for discovering needed
therapies beyond glycemic control and angiotensin II in-
hibition for the treatment of diabetic nephropathy; (6)
signaling pathways downstream of angiotensin II repre-
sent prime targets for additional therapeutic interven-
tions; (7) hypothesis-driven basic research on individual
pathways has (and likely will continue to) shed light on
the complexities of the pathologic interactions and the
redundancies in the systems; (8) candidate gene studies
are the genetic analogues of this type of hypothesis-driven
basic research; (9) microarray and genomic scanning cou-
pled with informatics technology offer the possibility of
modeling these complex system interactions and hope-
fully will allow us to identify optimal targets for inhibition
and/or up-regulation that can prevent progression and
restore structure and function; and (10) given the redun-
dancy and convergence of these pathways, the challenge
will be in graded inhibition that will preserve salutary
pathways, but inhibit deleterious ones.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Professor of Medicine,
Tufts University School of Medicine, Boston, Mas-
sachusetts): The one factor that is most interesting to me is
the 12-HETE factor. Perhaps you can tell us more about
the genesis of either your or other people’s interest in it.
Also, does 12-HETE work only in the kidney, or is 12-
HETE producing other comparable diabetic end organ
changes, such as neuropathy and retinopathy?
DR. ADLER: Actually that pathway has been exten-
sively explored by my colleagues and collaborators Rama
Natarajan and Jerry Nadler. As you might anticipate from
this talk, in fact it does work in many, many organ sys-
tems. Jerry has shown that 12/15-LO knockout mice are
relatively resistant to the induction of diabetes by strep-
tozotocin, most likely because the 12/15-LO pathway also
modulates reactive active oxygen species [73]. Rama has
shown that the pathway is activated in breast carcinoma
cells [74]. Rama has shown that it is active not just in re-
nal arteries and arterioles, but in extrarenal VSMCs. It
mediates proliferation in atherosclerosis [75]. So, yes, the
12/15-LO pathway behaves like the RAS itself, in that it
functions in various tissues in rather tissue-specific ways.
DR. RAJNISH MEHROTRA (Assistant Professor of
Medicine, David Geffen School of Medicine at UCLA,
Los Angeles, California): The end product of the signal-
ing pathway that you focused on is proliferation. You said
the same pathways work in the tubulointerstitium but, at
least for the tubules, the end product is atrophy and not
proliferation. How do you mesh that all together?
DR. ADLER: Thank you for that question. Given that
Dr. Harrington only gave me 55 minutes and not a week,
there are some things that I actually left out! Certainly
at the beginning of diabetic nephropathy one gets tubu-
lar hypertrophy and probably some proliferation because
that’s how you get increased renal mass. But, in the end,
you do get tubular atrophy and interstitial fibrosis. One of
the mediating systems that I didn’t talk about with respect
to angiotensin II is its interaction with the AT2 receptor.
The AT2 receptor appears to regulate apoptosis. One
might posit that in early and late diabetic nephropathy
there is differential activation of the AT1 and AT2 recep-
tors. Activation of the former would favor mass accrual
by hypertrophy and proliferation, whereas activation of
AT2 would favor apoptosis. In fact it has been shown
that in overt diabetic nephropathy, the ratio of AT1/AT2
expression is diminished in tubules [31], suggesting dif-
ferential expression.
DR. ARTHUR COHEN (Professor of Pathology, David
Geffen School of Medicine at UCLA): How is it that dia-
betes alters or reduces nephrin? A related question: how
long does diabetes need to be present before that occurs
and, if for only a short time, do we see foot process ef-
facement early in diabetes without proteinuria?
DR. ADLER: The signaling pathways that link an-
giotensin to nephrin expression have not, to my knowl-
edge, been worked out. The decrement in nephrin does
occur as early as microalbuminuria, at least according to
the immunofluorescent studies that were published ear-
lier this year [27]. I do not know for sure whether there is
podocyte effacement in patients with microalbuminuria.
One of our hypotheses is that podocyte effacement is one
of the earliest lesions associated with microalbuminuria.
In streptozotocin-induced rat studies that we are doing,
we hope to demonstrate that. In rats the earliest stud-
ies that I know of are at 6 months where there’s podocyte
effacement, but that is a more developed renal lesion and
it is not really a microalbuminuria lesion [19].
DR. STANLEY JORDAN (Profess of Pediatrics, David
Geffen School of Medicine at UCLA): I have two
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questions. First, the 12/15-LO pathway certainly looks
like a very critical lynch pin pathway to inhibit to prevent
some of the diabetic renal complications. Is any work
being done on the lipoxygenase pathway inhibitors in ex-
perimental diabetic nephropathy?
DR. ADLER: In our collaboration with Dr. Natarajan,
we have looked at three 12/15-LO pathway inhibitors al-
ready. What we have found so far is that we can inhibit
12/15-LO. However, at least with the one inhibitor stud-
ied so far for the longest period of time, there tends to
be tachyphylaxis, with early inhibition (days) followed
in weeks by overexpression of 12/15-LO. Interestingly
enough, however, those studies did show that there’s
a tight relationship between the expression of urinary
12-HETE, the product of 12/15-LO activation, and the
amount of urinary protein excretion [abstract; Adler SG,
et al J Am Soc Nephrol 14:332A, 2003]. It would appear,
then, that sustained inhibition of the pathway might be
antiproteinuric. We are exploring additional compounds
to test this hypothesis.
DR. JORDAN: Mycophenolate mofetil (MMF) has been
shown to inhibit progression to renal failure in 5/6
nephrectomized animals. MMF appeared to inhibit pro-
teinuria through a pathway that was independent of hy-
perfiltration and related to monocyte and macrophage
activation and inhibition of TGF-b and collagen synthe-
sis. Do you think that might be an interesting area to
explore?
DR. ADLER: Yes, I think that’s a very interesting idea.
It’s been well known for some time that drugs that are
used for immune mediation like prednisone or like MMF
have effects even in non-immune renal disorders, and it’s
entirely likely that those are mediated by these intersect-
ing pathways. While I don’t think this has been adequately
studied to recommend it as a clinical strategy, it’s certainly
an intriguing notion that these pathways may be modu-
lated by drugs generally used for other purposes.
DR. MIKE BUNNAPRADIST (Assistant Professor of
Medicine, David Geffen School of Medicine at UCLA):
Are there differences between the pathophysiology of
nephropathy in type 1 and type 2 diabetes? For instance,
the incidence of retinopathy is higher in patients with
type 1 than in type 2 diabetes with nephropathy. Would
that difference be due to the actions of two different
mechanisms?
DR. ADLER: Certainly, histologically the nephropathy
looks very much alike. I think a pathologist would be
hard-pressed to distinguish one from the other. However,
I think that there probably are differences, particularly
when it comes to the arterial and arteriolar change, which
I think is probably more advanced in patients with type 2
disease than in patients with type 1 disease. This, however,
may reflect patient age rather than diabetes type. Another
difficulty in making comparisons between the two is the
problem of not being able to ascertain with certainty the
duration of diabetes in patients with type 2 disease as
well as in patients with type 1 disease, making glycemic
exposure over time a variable for which it is difficult to
control.
DR. DAVID LEE (Professor of Medicine, David Gef-
fen School of Medicine at UCLA): Hyperglycemia and
angiotensin II appear to be the basic culprits in the initia-
tion and maintenance of the cascades of events that lead
to damage in the kidney. These events, presumably, oc-
cur in patients with or without nephropathy. The fact that
a significant proportion of patients with diabetes do not
develop nephropathy raises the possibility of additional
resistance/susceptibility factors, genetic or otherwise. It
would appear the elucidation of such factors would be as
important as the apparent etiologic factors you have so
well and comprehensively addressed. I’d appreciate your
thoughts on this issue.
DR. ADLER: I think that that kind of clinical obser-
vation is really the underpinning for the concept that
there is genetic predisposition. Interestingly enough, an-
giotensin II stimulates the mesangial cell glucose trans-
porter Glut 1, and so one can imagine, for instance, that
predisposition to diabetic nephropathy relates to poly-
morphisms in those glucose transporters [76, 77]. So, ge-
netically defined alterations in glucose transporters, for
instance, which might be interacting with the angiotensin
II system, may define who develops diabetic complica-
tions and who doesn’t. With the information we get from
the FIND study, I hope that in the next couple of years
we will be able to identify such genes [1].
DR. STANLEY FRANKLIN (Professor Emeritus, Univer-
sity of California at Irvine School of Medicine, Irvine, Cal-
ifornia): It would appear that tissue angiotensin II seems
to be a prime mover in diabetic vasculopathy. Yet we have
a paradox in advanced diabetes where there is a decrease
in plasma renin activity despite extremely high levels of
renal tissue angiotensin II. At times, the advanced dia-
betic nephropathy patient may present with a hyporenin,
hypoaldosterone syndrome. Thus, there appears to be a
disconnect between the circulating and the tissue renin-
angiotensin-aldosterone systems. Do you have any ex-
planation for this paradox? Is it possible that advanced
diabetic nephropathy has so affected the juxtaglomeru-
lar apparatus that it loses its ability to secrete renin and
generate circulating angiotensin II despite massive tissue
angiotensin II levels?
DR. ADLER: It’s important to remember that the stim-
ulus is not just glucose and the local tissue stimuli may
be quite different. In fact the amount of angiotensin II in
renal parenchyma is 1000 times higher than it is in the cir-
culation. For instance, in mesangial cells there is a novel
peptidase that’s not chymase that converts angiotensin 1-
9 to active angiotensin II [12]. But your observation that
tissue levels are important is underscored by a recent pre-
sentation at the ASN [abstract; Montero A, et al J Am
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Soc Nephrol 14:129A, 2003] that showed that ACE3 mice,
which are genetically modulated so that they make ACE
almost exclusively in the liver and have minimal renal ac-
tivity, have less albuminuria, glomerular TGF-b1 mRNA,
and collagen 1 mRNA than diabetic control mice.
DR. HARVEY GONICK (Clinical Professor of Medicine,
David Geffen School of Medicine at UCLA): Sharon, I
have two connected questions. You alluded to the fact
that angiotensin II is associated with increased ROS.
Have you ever tried to see whether or not the increased
ROS can trigger the events that you described so well?
DR. ADLER: I have not, but I’m sure that others have.
I’m not entirely familiar with that literature.
DR. GONICK: My second question has to do with reno-
vascular hypertension. Renovascular hypertension is the
sine qua non for very high angiotensin II levels, and
yet I don’t recall ever seeing the pathology of diabetic
nephropathy in the affected unilateral kidney.
DR. ADLER: One can argue that you see the pathol-
ogy of diabetic nephropathy if one includes ischemia due
to arterial/arteriolar disease as an integral feature of the
diabetic lesion. If you don’t include vascular change and
the resultant ischemic nephropathy as part of the lesion,
then I guess one can argue that you don’t see it. I think the
issue is a semantic one more than a biologic one. It is cer-
tainly true that ischemia in the absence of diabetes does
not induce mesangial expansion. So it is likely that high
systemic levels of angiotensin II acting at the level of the
vasculature induce the arterial/arteriolar lesion, but not
the mesangial lesion, and only the autocrine/paracrine
activation of the RAS at the level of the mesangial cell
induces mesangial expansion. No doubt the effects of an-
giotensin II are also synergistically modulated by a hy-
perglycemic environment.
DR. JACK COBURN (Professor of Medicine, David Gef-
fen School of Medicine at UCLA): From a therapeutic
standpoint, there’s growing data suggesting that combi-
nations of angiotensin receptor blockers and ACE in-
hibitors may be additive in their effects. Do you have
reasons or ideas on why this may be?
DR. ADLER: In the kidney, about 15% to 30% of the
angiotensin II is not synthesized via the renin-ACE path-
way but through another pathway mediated by chymases.
There may also be a novel peptidase that synthesizes an-
giotensin II from angiotensin 1-9 [12].
If you depend entirely on ACE inhibition to block an-
giotensin II synthesis in the kidney, you will miss up to
30% of the total angiotensin II that is synthesized by other
pathways. Thus, to block the effects of that angiotensin
II that evades ACE inhibition, it becomes necessary to
block the receptor directly. In nondiabetic proteinuric
patients, this has been well demonstrated by the COOP-
ERATE study, in which ACE inhibitors and angiotensin
receptor blockers were demonstrated to be synergistic
in their effects on a combined composite end point of
renal function, mortality, and morbidity independent of
blood pressure control [78]. In a small study of diabetic
subjects (N = 16), the addition of candesartan to a max-
imally dosed ACE inhibitor further lowered proteinuria
without significantly diminishing blood pressure further
[79].
DR. LAWRENCE GUZIEL (Assistant Clinical Professor
of Medicine, David Geffen School of Medicine at UCLA):
Dr. Laragh has published a couple of papers, one in the
1970s and I think in the 1990s, regarding low renin essen-
tial hypertension having a better prognosis and less car-
diovascular mortality. Could that possibly be related to
lower levels of serum angiotensin or in tissue angiotensin
or a combination of both?
DR. ADLER: That’s a very interesting thought. While
it’s a possibility, there remain certain paradoxes regard-
ing renin levels. In low-renin hypertension, one might
posit that the synthesis of angiotensin II would be lim-
ited due to diminished substrate availability (angiotensin
I) for angiotensin II generation by chymases and con-
verting enzyme. In fact, renin blockers have been in the
development stage for some time. It is possible that renin
inhibitors would be ideal agents to add to ACE inhibitors
because of this property.
DR. HARRINGTON: You mentioned Liu’s data from
China [abstract; Liu Z-H et al J Am Soc Nephrol 14:400A,
2003], which overwhelmed me. Apparently there are 182
genes whose expression is up- or down-regulated signifi-
cantly in patients with diabetes. If I asked you to pick the
“top three” genes other than the ACE polymorphisms,
which three would you choose and why?
DR. ADLER: Well, actually I didn’t see all of their re-
sults nor did they report all 182. But I guess my favorite
ones would be some that relate to the ROS pathway
because this is an all-purpose pathway of cell injury fu-
eled by a hyperglycemic environment; some that relate
to podocyte structure to explain the development of pro-
teinuria; and TGF-b , which is a master regulator of scle-
rosis and fibrosis.
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